Fengcai Zhu to Adolescent
This is a "connection" page, showing publications Fengcai Zhu has written about Adolescent.
Connection Strength
0.306
-
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021 07 15; 6(1):271.
Score: 0.026
-
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070.
Score: 0.026
-
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 02; 21(2):181-192.
Score: 0.025
-
COVID-19 outbreak following a single patient exposure at an entertainment site: An epidemiological study. Transbound Emerg Dis. 2021 Mar; 68(2):773-781.
Score: 0.025
-
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488.
Score: 0.025
-
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 06 13; 395(10240):1845-1854.
Score: 0.024
-
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019 10; 8(14):6195-6211.
Score: 0.023
-
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort. J Viral Hepat. 2018 12; 25(12):1588-1598.
Score: 0.022
-
Preliminary fast diagnosis of severe fever with thrombocytopenia syndrome with clinical and epidemiological parameters. PLoS One. 2017; 12(7):e0180256.
Score: 0.020
-
The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial. Hum Vaccin Immunother. 2017 06 03; 13(6):1-6.
Score: 0.019
-
Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine. 2014 Jun 17; 32(29):3706-12.
Score: 0.016
-
A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009 Dec 17; 361(25):2414-23.
Score: 0.012
-
Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020 08; 285:198005.
Score: 0.006
-
Association of viral load with serum biomakers among COVID-19 cases. Virology. 2020 07; 546:122-126.
Score: 0.006
-
Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China. BMC Infect Dis. 2019 Jul 12; 19(1):617.
Score: 0.006
-
Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci China Life Sci. 2020 Apr; 63(4):582-591.
Score: 0.006
-
The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study. Vaccine. 2018 01 04; 36(2):256-263.
Score: 0.005
-
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. Expert Rev Vaccines. 2017 11; 16(11):1155-1169.
Score: 0.005
-
Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine. 2017 10 09; 35(42):5644-5652.
Score: 0.005
-
A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine. 2017 09 05; 35(37):5073-5080.
Score: 0.005